FOXO TECHNOLOGIES INC.

FOXO Technologies Inc., trading under the ticker FOXO, filed its final prospectus on Form 424B4 with the SEC on December 11, 2020, marking its entry into the public markets. The company operates at the intersection of insurtech and longevity science, applying epigenetic biomarker research to life insurance underwriting with the aim of improving risk assessment accuracy for carriers. FOXO positions itself within the broader life insurance and financial technology sector, leveraging proprietary data analysis to evaluate policyholder longevity risk. The company subsequently pursued a de-SPAC transaction through Delwinds Insurance Acquisition Corp. to complete its public market transition. For full filing history, sponsor details, deal timeline, and current FOXO status, sign up for complete data access at SpacDesk.